Armstrong AJ - Search Results

1

Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).

Sonpavde G, Wang CG, Galsky MD, Oh WK, Armstrong AJ. Sonpavde G, et al. Among authors: armstrong aj. BJU Int. 2015 Jul;116(1):17-29. doi: 10.1111/bju.12867. Epub 2014 Oct 23. BJU Int. 2015. PMID: 25046451 Review.

2

Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.

Armstrong AJ, Carducci MA. Armstrong AJ, et al. Curr Oncol Rep. 2005 May;7(3):220-7. doi: 10.1007/s11912-005-0077-y. Curr Oncol Rep. 2005. PMID: 15847714 Review.

3

Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.

Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, Eisenberger M. Armstrong AJ, et al. J Clin Oncol. 2007 Sep 1;25(25):3965-70. doi: 10.1200/JCO.2007.11.4769. J Clin Oncol. 2007. PMID: 17761981 Clinical Trial.

4

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.

Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. Armstrong AJ, et al. Clin Cancer Res. 2007 Nov 1;13(21):6396-403. doi: 10.1158/1078-0432.CCR-07-1036. Clin Cancer Res. 2007. PMID: 17975152 Clinical Trial.

5

Cell signaling modifiers in prostate cancer.

Chen FL, Armstrong AJ, George DJ. Chen FL, et al. Among authors: armstrong aj. Cancer J. 2008 Jan-Feb;14(1):40-5. doi: 10.1097/PPO.0b013e318161d40f. Cancer J. 2008. PMID: 18303482 Review.

6

Clinical endpoints for drug development in prostate cancer.

Ramiah V, George DJ, Armstrong AJ. Ramiah V, et al. Among authors: armstrong aj. Curr Opin Urol. 2008 May;18(3):303-8. doi: 10.1097/MOU.0b013e3282fb7807. Curr Opin Urol. 2008. PMID: 18382240 Review.

7

New drug development in metastatic prostate cancer.

Armstrong AJ, George DJ. Armstrong AJ, et al. Urol Oncol. 2008 Jul-Aug;26(4):430-7. doi: 10.1016/j.urolonc.2007.11.006. Urol Oncol. 2008. PMID: 18593623 Review.

8

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.

Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ. Armstrong AJ, et al. Clin Cancer Res. 2008 Oct 1;14(19):6270-6. doi: 10.1158/1078-0432.CCR-08-1085. Clin Cancer Res. 2008. PMID: 18829508 Clinical Trial.

9

Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.

Armstrong AJ, Febbo PG. Armstrong AJ, et al. Oncologist. 2009 Aug;14(8):816-27. doi: 10.1634/theoncologist.2009-0043. Epub 2009 Aug 14. Oncologist. 2009. PMID: 19684076 Free article. Review.

10

The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.

Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. Armstrong AJ, et al. Eur J Cancer. 2010 Feb;46(3):517-25. doi: 10.1016/j.ejca.2009.11.007. Epub 2009 Dec 11. Eur J Cancer. 2010. PMID: 20005697 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

388 results

Search Page

Filters